ZyVersa Therapeutics is focused on developing innovative therapies targeting inflammatory and renal diseases through two primary technologies: inflammasome inhibition and cholesterol efflux mediation. The company is advancing IC 100, a monoclonal antibody designed to inhibit the adaptor protein ASC within the inflammasome complex. This approach aims to block the initiation and perpetuation of inflammatory cascades that can lead to various chronic inflammatory diseases. By targeting inflammasomes, ZyVersa seeks to mitigate the excessive immune responses that contribute to conditions such as obesity and its associated health complications.

In addition to inflammasome inhibition, ZyVersa is developing VAR 200, a cholesterol efflux mediator that addresses the accumulation of excess cholesterol in the kidneys, a common issue in chronic kidney diseases. This technology aims to enhance the removal of cholesterol from the kidney's filtration system, thereby protecting against structural damage, reducing proteinuria, and preserving renal function. Through these innovative approaches, ZyVersa Therapeutics is committed to improving health outcomes and quality of life for patients suffering from inflammatory and renal diseases.

United States

ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging two licensed proprietary product platforms to develop pharmaceutical products that address unmet medical needs in the areas of renal and inflammatory diseases.

Lead renal candidate, Phase 2a-ready VAR 200, mediates removal of excess intracellular lipids in the kidney’s filtration system that contribute to kidney damage leading to end-stage kidney disease.

Lead anti-inflammatory drug candidate, inflammasome ASC inhibitor (IC 100), blocks initiation and perpetuation of damaging inflammation that’s pathogenic in a multitude of inflammatory diseases.

ZyVersa Therapeutics

Company Details